Năng lực sản xuất bổ sung cho vắc xin COVID-19 của BioNTech / Pfizer

EMA has recommended the approval of additional manufacturing and filling lines at Pfizer’s vaccine manufacturing site in Puurs, Belgium. The recommendation by the Agency’s Committee for Human Medicines (CHMP) is expected to have a significant and immediate impact on the supply of Comirnaty, the COVID-19 vaccine developed by BioNTech and Pfizer, in the European Union.

Based on the review of the data submitted by BioNTech Manufacturing GmbH, EMA’s decision reaffirms that the Puurs facility is capable of consistently producing high-quality vaccines and enables Pfizer/BioNTech to increase the volumes of vaccines produced at this site.

Hôm nay @EMA_News recommended the approval of a further increase in production at BioNTech/Pfizer’s Puurs site.

This is a very welcome step towards stepping up our manufacturing capacity within 🇪🇺 and delivering vaccines faster across the world ➡️ https://t.co/Q6JmvU5Hbj

- Stella Kyriakides (@SKyriakidesEU) 1 Tháng Sáu, 2021

Những thay đổi được mô tả sẽ được đưa vào thông tin công khai về loại vắc xin này trên trang web của EMA.

Nội dung liên quan

• Công ty: EPAR
• Comirnaty: Paediatric investigation plan

Nội dung liên quan

• Bệnh coronavirus (COVID-19)
• COVID-19: cập nhật mới nhất
• COVID-19 vaccines: authorized
• Vắc xin COVID-19: phát triển, đánh giá, phê duyệt và giám sát
• Committee for Medicinal Products for Human Use (CHMP)

quảng cáo

Chia sẻ bài viết này: